Picard Celebrates Patient Living a World-Record of Over Eight Years with the SynCardia Total Artificial Heart

Core Insights - Picard Medical marks a historic milestone with a patient living 2,900 days on the SynCardia Total Artificial Heart, the longest duration recorded globally [1][2] Company Overview - Picard Medical, Inc. is the parent company of SynCardia Systems, LLC, which produces the only commercially available total artificial heart technology approved by the U.S. FDA and Health Canada [5] - The SynCardia Total Artificial Heart (STAH) is designed for patients with end-stage heart failure and has been implanted over 2,100 times across 27 countries, making it the most widely used artificial heart [5] Patient Achievement - A 46-year-old patient received the SynCardia Total Artificial Heart on December 9, 2017, and has lived for over eight years, primarily at home with family [3] - This achievement highlights the effectiveness of the SynCardia technology and the dedication of the medical team at IVDK Dedinje Hospital in Serbia [3] Long-term Success in Serbia - Serbia leads in long-duration support with the SynCardia Total Artificial Heart, with the five longest-supported patients globally all from IVDK Dedinje Hospital [4] - The hospital has demonstrated exceptional clinical success, with one patient supported for about eight years and others for durations ranging from three to four years [4] Future Developments - Building on the success of the STAH, Picard Medical is developing the Emperor, a next-generation fully implantable artificial heart system aimed at broadening access and providing greater flexibility for long-term support [2]